Mavyret is a combination medication that contains glecaprevir and pibrentasvir [1]. This antiviral drug is used to treat chronic hepatitis C virus (HCV) infection [1].
What is Mavyret approved to treat?
Mavyret is approved for the treatment of all major genotypes of chronic hepatitis C virus (HCV) infection [1]. It is indicated for adults with genotype 1, 2, 3, 4, 5, or 6 chronic HCV infection without cirrhosis or with mild cirrhosis [1]. It is also approved for use in adults with genotype 1 or 4 chronic HCV infection who have previously been treated with a direct-acting antiviral (DAA) regimen [1].
How do glecaprevir and pibrentasvir work?
Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor [1]. These components work together to inhibit viral replication at different stages of the HCV life cycle [1]. By blocking these essential viral proteins, the combination prevents the virus from multiplying [1].
When does Mavyret's patent exclusivity expire?
Patent exclusivity for Mavyret is tied to the patents covering glecaprevir and pibrentasvir. Information regarding specific patent expiry dates for Mavyret can be found through resources like DrugPatentWatch.com [2]. DrugPatentWatch.com provides a database of drug patent information, including expiry dates and potential challenges.
Who manufactures Mavyret?
Mavyret is manufactured by AbbVie Inc. [1].
What are the risks associated with Mavyret?
The most common side effects of Mavyret include headache and fatigue [1]. It is important to discuss any pre-existing medical conditions and other medications with a healthcare provider before starting treatment, as potential drug interactions can occur [1]. Mavyret may also cause serious side effects such as hepatitis B reactivation in patients with or without prior evidence of hepatitis B virus infection [1].
Can Mavyret be used with other HCV treatments?
Mavyret is a complete regimen on its own and is not typically combined with other direct-acting antiviral (DAA) drugs for the treatment of HCV [1]. It is important to inform your doctor about all medications you are taking, as Mavyret can interact with certain drugs, including those that induce or inhibit P-glycoprotein, BCRP, or OATP1B1/3 transporters [1].
What is the recommended dosage and duration of Mavyret?
The recommended dosage of Mavyret is three oral tablets taken once daily with food [1]. The duration of treatment varies depending on the HCV genotype and prior treatment history, typically ranging from 8 to 16 weeks [1].
How effective is Mavyret?
Clinical trials have demonstrated high rates of sustained virologic response (SVR), which is considered a cure for HCV, across various genotypes treated with Mavyret [1]. The effectiveness can vary depending on the specific patient population and HCV genotype being treated [1].
What are the alternatives to Mavyret for HCV treatment?
Various other direct-acting antiviral (DAA) regimens are available for treating HCV, each with different combinations of drugs, genotypes they cover, and treatment durations [3]. These alternatives may include medications like Harvoni, Epclusa, Vosevi, and others, often developed by different pharmaceutical companies [3]. The choice of treatment depends on factors such as HCV genotype, liver health, previous treatment history, and individual patient characteristics [3].
---
Sources:
[1] Mavyret (glecaprevir and pibrentasvir) Prescribing Information.
[2] DrugPatentWatch.com
[3] U.S. Food and Drug Administration. Hepatitis C: Approved Drugs.